Summary
February 2008, Vol. 9, No. 3, Pages 351-362 , DOI 10.1517/14656566.9.3.351

Pharmacotherapy of insomnia

Abid Bhat1 MD, Fariha Shafi2 MD & Ali A El Solh3 MD MPH
1University of Missouri at Kansas City, Division of Pulmonary and Critical Care Medicine, Geriatrics and Hospital Medicine, Department of Medicine, Truman Medical Center, Hospital Hill, Kansas City, Missouri, USA
2University of Missouri at Kansas City, Division of General Internal Medicine, Geriatrics and Hospital Medicine, Department of Medicine, Truman Medical Center, Hospital Hill, Kansas City, Missouri, USA
3State University of New York at Buffalo, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA +1 716 898 3375; +1 716 898 6139;
Author for correspondence



Insomnia is the most common sleep disorder in the industrialized world. A variety of precipitating events have been identified, but when it becomes a persistent problem, maladaptive patterns become established, thereby, perpetuating the sleep disturbance. Individuals with insomnia have impaired next-day functioning, which impacts their quality of life and places them at increased risk of motor vehicle accidents. Insomnia is commonly associated with chronic medical conditions, as well as an increased incidence of mental disorders. Despite considerable scientific advances in both the understanding and treatment, insomnia continues to be inadequately identified and treated, with < 15% of those with severe insomnia receiving appropriate treatment. The mainstay of treatment for insomnia is cognitive-behavioral therapy, along with judicious use of hypnotic agents.

Full Text | PDF (146 KB) | PDF Plus (271 KB)

Forward Links to Citing Articles

Marshall E. Cates, Cherry W. Jackson, Jacqueline M. Feldman, Amanda E. Stimmel, Thomas W. Woolley. (2009) Metabolic Consequences of Using Low-Dose Quetiapine for Insomnia in Psychiatric Patients. Community Mental Health Journal
Online publication date: 27-Jun-2009.
CrossRef

Users who read this article also read:

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?
Sheila A Doggrell
Expert Opinion on Pharmacotherapy, Feb 2008, Vol. 9, No. 3, Pages 405-420.
Summary | Full Text | PDF (158 KB) | PDF Plus (350 KB) | Add to Favorites | Related 
Diagnosis and treatment of vitamin D deficiency
JJ Cannell, BW Hollis, M Zasloff, RP Heaney
Expert Opinion on Pharmacotherapy, Jan 2008, Vol. 9, No. 1, Pages 107-118.
Summary | Full Text | PDF (145 KB) | PDF Plus (281 KB) | Add to Favorites | Related 
Colon cancer: preventive agents and the present status of chemoprevention
Elizabeth Half, Nadir Arber
Expert Opinion on Pharmacotherapy, Feb 2009, Vol. 10, No. 2, Pages 211-219.
Summary | Full Text | PDF (241 KB) | PDF Plus (198 KB) | Add to Favorites | Related 
Desvenlafaxine succinate for the treatment of major depressive disorder
Falk W Lohoff, Karl Rickels
Expert Opinion on Pharmacotherapy, Aug 2008, Vol. 9, No. 12, Pages 2129-2136.
Summary | Full Text | PDF (222 KB) | PDF Plus (196 KB) | Add to Favorites | Related 
An update on the treatment of bipolar depression
Jean-Michel Azorin, Arthur Kaladjian
Expert Opinion on Pharmacotherapy, Feb 2009, Vol. 10, No. 2, Pages 161-172.
Summary | Full Text | PDF (258 KB) | PDF Plus (215 KB) | Add to Favorites | Related 
Burns: what are the pharmacological treatment options?
Robert H Demling
Expert Opinion on Pharmacotherapy, Aug 2008, Vol. 9, No. 11, Pages 1895-1908.
Summary | Full Text | PDF (311 KB) | PDF Plus (289 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (146 KB)
View PDF Plus (271 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Abid Bhat
Fariha Shafi
Ali A El Solh
Keywords:
benzodiazepine
benzodiazepine receptor agonist
insomnia
melatonin
total sleep time